Literature DB >> 8721775

Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study.

J M Mooy1, P A Grootenhuis, H de Vries, P J Kostense, C Popp-Snijders, L M Bouter, R J Heine.   

Abstract

We studied the intra-individual variation in plasma glucose, specific serum insulin and serum proinsulin concentrations, measured by two 75-g oral glucose tolerance tests in an age, sex, and glucose tolerance stratified random sample from a 50-74-year-old Caucasian population without a history of diabetes mellitus. The intra-individual variation was assessed by the standard deviation of the test-retest differences (SDdif). For subjects with normal (n = 246), impaired glucose tolerance (n = 198), and newly detected diabetes (n = 80) classified at the first test, the following (SDdif/median level of individual average scores) were found: fasting glucose: 0.4/5.4, 0.5/5.9 and 0.7/7.2 mmol/l; 2-h glucose: 1.3/5.6, 1.8/8.5 and 2.3/12.8 mmol/l; fasting insulin: 23/76, 32/89 and 30/116 pmol/l; 2-h insulin: 190/303, 278/553 and 304/626 pmol/l; fasting proinsulin: 4/8, 6/13 and 9/18 pmol/l; 2-h proinsulin: 19/49, 23/84 and 33/90 pmol/l, respectively. In both glucose, proinsulin and insulin concentrations the total intra-individual variation was predominantly determined by biological variation, whereas analytical variation made only a minor contribution. The SDdif can easily be interpreted, as 95% of the random test-retest differences will be less than 2.SDdif, or in terms of percentage, less than (2.SDdif/median level of individual average score) 100. Therefore, for subjects with normal glucose tolerance, 95% of the random test-retest differences will be less than 15% (fasting glucose), 46% (2-h glucose), 61% (fasting insulin), 125% (2-h insulin), 100% (fasting proinsulin) and 78% (2-h proinsulin) of the median value of the individual average scores. No substantial independent association of either age, gender or obesity with the intra-individual variation in glucose, proinsulin, or insulin concentrations was found.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8721775     DOI: 10.1007/BF00418345

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  15 in total

1.  Raised proinsulin concentration as early indicator of beta cell dysfunction.

Authors:  D R Williams; C Byrne; P M Clark; L Cox; N E Day; G Rayman; T Wang; C N Hales
Journal:  BMJ       Date:  1991-07-13

2.  Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart.

Authors:  J M Olefsky; G M Reaven
Journal:  Diabetes       Date:  1974-05       Impact factor: 9.461

3.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

4.  Study in Tanzania of impaired glucose tolerance. Methodological myth?

Authors:  A B Swai; D G McLarty; H M Kitange; P M Kilima; G Masuki; B I Mtinangi; L Chuwa; G M Alberti
Journal:  Diabetes       Date:  1991-04       Impact factor: 9.461

5.  Reproducibility of the new diagnostic criteria for impaired glucose tolerance.

Authors:  G Riccardi; O Vaccaro; A Rivellese; S Pignalosa; L Tutino; M Mancini
Journal:  Am J Epidemiol       Date:  1985-03       Impact factor: 4.897

6.  Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins.

Authors:  W J Sobey; S F Beer; C A Carrington; P M Clark; B H Frank; I P Gray; S D Luzio; D R Owens; A E Schneider; K Siddle
Journal:  Biochem J       Date:  1989-06-01       Impact factor: 3.857

7.  Effectiveness of glycosylated hemoglobin, fasting plasma glucose, and a single post load plasma glucose level in population screening for glucose intolerance.

Authors:  M Modan; H Halkin; A Karasik; A Lusky
Journal:  Am J Epidemiol       Date:  1984-03       Impact factor: 4.897

8.  How good a marker is insulin level for insulin resistance?

Authors:  M Laakso
Journal:  Am J Epidemiol       Date:  1993-05-01       Impact factor: 4.897

9.  The abbreviated glucose tolerance test in screening for diabetes: the Islington Diabetes Survey.

Authors:  R D Forrest; C A Jackson; J S Yudkin
Journal:  Diabet Med       Date:  1988-09       Impact factor: 4.359

10.  Screening for diabetes: does measurement of serum fructosamine help?

Authors:  A B Swai; K Harrison; L M Chuwa; W Makene; D McLarty; K G Alberti
Journal:  Diabet Med       Date:  1988-10       Impact factor: 4.359

View more
  88 in total

1.  Oral glucose tolerance test in patients with undiagnosed diabetes and coronary artery disease: when should it be performed?

Authors:  A Kollias; E Diamanti-Kandarakis
Journal:  Diabetologia       Date:  2012-02-04       Impact factor: 10.122

2.  HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards.

Authors:  N Sattar; D Preiss
Journal:  Diabetologia       Date:  2012-03-08       Impact factor: 10.122

3.  Pitfalls of HbA1c in the Diagnosis of Diabetes.

Authors:  Michael Bergman; Muhammad Abdul-Ghani; João Sérgio Neves; Mariana P Monteiro; Jose Luiz Medina; Brenda Dorcely; Martin Buysschaert
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 5.958

4.  Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care.

Authors:  Denice S Feig; Valerie A Palda; Lorraine Lipscombe
Journal:  CMAJ       Date:  2005-01-18       Impact factor: 8.262

5.  When a placebo is not a 'placebo': a placebo effect on postprandial glycaemia.

Authors:  John L Sievenpiper; Adish Ezatagha; Anamaria Dascalu; Vladimir Vuksan
Journal:  Br J Clin Pharmacol       Date:  2007-05-17       Impact factor: 4.335

Review 6.  Performance characteristics of postpartum screening tests for type 2 diabetes mellitus in women with a history of gestational diabetes mellitus: a systematic review.

Authors:  Wendy L Bennett; Shari Bolen; Lisa M Wilson; Eric B Bass; Wanda K Nicholson
Journal:  J Womens Health (Larchmt)       Date:  2009-07       Impact factor: 2.681

Review 7.  Impaired fasting glucose as a treatment target in diabetes management.

Authors:  Rene A Oliveros; Adrienne S Zion; Yelena Rosenberg; Carrie Lynn Selvaraj; Robert Chilton
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

8.  Lifetime risk and projected population prevalence of diabetes.

Authors:  D J Magliano; J E Shaw; S M Shortreed; W J Nusselder; D Liew; E L M Barr; P Z Zimmet; A Peeters
Journal:  Diabetologia       Date:  2008-09-23       Impact factor: 10.122

9.  Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies.

Authors: 
Journal:  Diabetologia       Date:  2004-07-07       Impact factor: 10.122

10.  Comparative evaluation of whole body and hepatic insulin resistance using indices from oral glucose tolerance test in morbidly obese subjects with nonalcoholic Fatty liver disease.

Authors:  Kamran Qureshi; Ronald H Clements; Fahad Saeed; Gary A Abrams
Journal:  J Obes       Date:  2010-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.